



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

28 Oct 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard ([eugeneb@sun.ac.za](mailto:eugeneb@sun.ac.za)), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

## Important notices

- [Application Missteps—Unfocused Hypothesis or Specific Aims](#) A pitfall to sidestep when applying for NIH funds: lack of focus in your hypothesis and Specific Aims.
- [Understanding Indirect Costs](#) Having trouble distinguishing between direct and indirect costs for your federally funded research project? Check out the Office of Extramural Research's YouTube presentation Indirect Costs 101.
- US and Canada partner to [invest \\$21 million for environmental and occupational health research hubs](#) in developing countries
- [Experimental Aerosol TB Vaccine Protects Monkeys](#)
- NIH study reveals [risk of drug-resistant malaria parasites spreading to Africa](#)
- Announcement of NIH Plans for the Environmental Influences on Child Health Outcomes (ECHO) Program ([NOT-OD-16-015](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Molecular and Cellular Analysis Technologies for Cancer Research (R21) ([NOT-CA-15-037](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) ([NOT-CA-15-039](#))
- Emerging Molecular Analysis Technologies for Cancer Research (R33) ([NOT-CA-15-038](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Technologies for Cancer-Relevant Biospecimen Science (R33) ([NOT-CA-15-040](#))
- Notice of Pre-application Webinar for PAR-15-286 and PAR-15-287 Opportunities for Collaborative Research at the NIH Clinical Center (X02 and U01) ([NOT-HD-15-031](#))
- Notice of Information Regarding Planned Webinar/Timing of Funding Opportunity Announcement for T4 Translation Research Capacity Building Initiative in Low Income Countries (TREIN) (U24) ([NOT-HL-15-277](#))

### 1. Title: B Cell Immunology Program for HIV-1 Vaccine Development (BCIP)

Letter of Intent due date: February 17, 2016

Hyperlink: [RFA-AI-15-055](#)

Type: RO1

**Application Due Date.** March 17, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.** Internal Submission will be 2 days before the application due date above.

**Purpose:** The objective of this FOA is to solicit hypothesis-driven, multidisciplinary research to elucidate the complexities and developmental plasticity of B cells associated with the induction of potent, durable, adaptive immune responses against HIV-1.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. Title: Adaptation/Optimization of Technology (ADOPTech) to Support Social Functioning

Letter of Intent due date: January 3, 2016

Hyperlink: [\(RFA-MH-17-150\)](#)

Type: R21

**Application Due Date:** February 3, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the development and testing of new, cutting-edge technologies to enhance functioning in individuals with social impairments. Projects funded under this FOA would create "social prosthetics": scalable technology or devices that would augment performance in this domain.

**Budget:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

**3. Title: Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)****Letter of Intent due date:** January 10, 2016**Hyperlink:** [RFA-AI-15-054](#)**Type:** R21/R33

**Application Due Date:** February 10, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

**Purpose:** The purpose of this FOA is to solicit applications to support early stage translational research focused on the discovery and development of novel therapeutics against select eukaryotic pathogens.

**Budget:** Application budgets are limited to \$275,000 in direct costs over the two-year project period, with a maximum of \$200,000 in direct costs allowed in any single year. The R33 award phase is limited to \$300,000 in direct costs per year. The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to two years of support for the R21 phase and up to 3 years of support for the R33 phase. The NIAID anticipates approximately 50% of the funded R21 phase awards will transition to the R33 award.

**4. Title: Genomic Data Analysis Network: Processing Genomic Data Center****Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [RFA-CA-15-018](#)**Type:** U24

**Application Due Date:** January 27, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

**Purpose:** This funding opportunity announcement (FOA) is a part of cancer genomics program supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. The acquired knowledge could facilitate and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This FOA solicits applications for a Processing Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-019 and RFA-CA-15-020). The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDAC to be supported under this FOA will be expected to focus on the integration and analysis of data generated by the GCCs and other project participants, development of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.

**Budget:** Application budgets are limited to \$660,000 direct costs per year. GDAC applicants should propose project periods of five years. Longer project periods are not permissible.

**5. Title: Genomic Data Analysis Network: Visualization Genomic Data Center****Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [RFA-CA-15-019](#)**Type:** U24

**Application Due Date:** January 27, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

**Purpose:** This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. The acquired knowledge could facilitate and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This FOA solicits applications for a Visualization Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-018 and RFA-CA-15-020). The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDAC to be supported under this FOA will be expected to focus on the development of visualization tools to facilitate the integration and analysis of data generated by the GCCs and other project participants, development of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.

**Budget:** Application budgets are limited to \$660,000 direct costs per year. GDAC applicants should propose project periods of five years. Longer project periods are not permissible.



**6. Title: Genomic Data Analysis Network: Specialized Genomic Data Center****Letter of Intent due date:** 30 days prior to application due date**Hyperlink:** [\(RFA-CA-15-020\)](#)**Type:** U24

**Application Due Date:** January 27, 2016 Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

**Purpose:** This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. The acquired knowledge could facilitate and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This FOA solicits applications for a Specialized Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-018 and RFA-CA-15-019). The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDACs to be supported under this FOA will be expected to focus on the intensive analysis of discrete sets of genomic platforms (core competencies) to facilitate the integration and analysis of data generated by the GCCs and other project participants, deployment of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.

**Budget:** Application budgets are limited to \$330,000 direct costs per year. GDAC applicants should propose project periods of five years. Longer project periods are not permissible.

**7. Title: Examination of Survivorship Care Planning Efficacy and Impact****Letter of Intent due date:** N/A**Hyperlink:** [\(PA-16-011\)](#)**Type:** R21[\(PA-16-012\)](#)

RO1

**Application Due Date:** **Standard dates apply**, Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date. Internal Submission will be 2 days before the application due date above.

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

**Budget: R21:** The combined budget for direct costs for the 2-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years. **RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

**Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)**

**DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award:** To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

**P20 – Research Program Projects and Centers -Exploratory Grant:** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 – Resource-Related Research Projects – Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

**Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa Coetsee** • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)